EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status

Rita Casadonte iD, Mark Kriegsmann iD, Katharina Kriegsmann, Helene Streit, Rolf Rüdiger Meliß, Cornelia S L Müller iD, Joerg Kriegsmann

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24065110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rita Casadonte und 6 weiteren Autor:innen. Beteiligte Einrichtung: Proteopath GmbH, 54296 Trier, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations of the oncogenes v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral oncogene homolog (NRAS) are the most frequent genetic alterations in melanoma and are mutually exclusive. BRAF V600 mutations are predictive for response to the two BRAF inhibitors vemurafenib and dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. However, inter- and intra-tumoral heterogeneity and the development of acquired resistance to BRAF inhibitors have important clinical implications. Here, we investigated and compared the molecular profile of BRAF and NRAS mutated and wildtype melanoma patients’ tissue samples using imaging mass spectrometry-based proteomic technology, to identify specific molecular signatures associated with the respective tumors. SCiLSLab and R-statistical software were used to classify peptide profiles using linear discriminant analysis and support vector machine models optimized with two internal cross-validation methods (leave-one-out, k-fold). Classification models showed molecular differences between BRAF and NRAS mutated melanoma, and identification of both was possible with an accuracy of 87–89% and 76–79%, depending on the respective classification method applied. In addition, differential expression of some predictive proteins, such as histones or glyceraldehyde-3-phosphate-dehydrogenase, correlated with BRAF or NRAS mutation status. Overall, these findings provide a new molecular method to classify melanoma patients carrying BRAF and NRAS mutations and help provide a broader view of the molecular characteristics of these patients that may help understand the signaling pathways and interactions involving the altered genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsMelanomaAnimalsMiceHumansProto-Oncogene Proteins B-rafProteomicsMutationProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesMass SpectrometryMembrane ProteinsGTP Phosphohydrolases

Stichwörter der Autor:innen

BRAFMALDINRASclassificationdiagnostics: imaging mass spectrometrymelanoma

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesBRAF protein, humanNRAS protein, humanMembrane ProteinsGTP Phosphohydrolases

Autor:innen und Institutionen

  • Proteopath GmbH, 54296 Trier, Germany.
  • Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Institute of Pathology Wiesbaden, 69120 Heidelberg, Germany.
  • Department of Hematology Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, 3500 Krems, Austria.
  • Institute für Dermatopathologie, 30519 Hannover, Germany.

ORCID-Profile: Rita Casadonte, Mark Kriegsmann, Cornelia S L Müller

Zitieren

APA

Casadonte, R., Kriegsmann, M., Kriegsmann, K., Streit, H., Meliß, R. R., Müller, C. S. L., & Kriegsmann, J. (2023). Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065110

Vancouver

Casadonte R, Kriegsmann M, Kriegsmann K, Streit H, Meliß RR, Müller CSL, et al. Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065110

BibTeX
@article{Casadonte2023,
  author = {Casadonte, Rita and Kriegsmann, Mark and Kriegsmann, Katharina and Streit, Helene and Meliß, Rolf Rüdiger and Müller, Cornelia S L and Kriegsmann, Joerg},
  title = {Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24065110}
}
Kostenlos starten →